ArticleBiochemistry and biophysics reports2025
Co-loaded simvastatin-ginsenoside Rh2 liposomes enhance cellular immune responses as vaccine adjuvants.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccine adjuvants are pivotal in novel vaccine development, enhancing immunization and modulating immune responses. This study prepared liposomes loaded with simvastatin and ginsenoside Rh2 (LIPO-SIM-Rh2) via high-speed shearing, rotary evaporation, and high-pressure homogenization. Using C57BL/6J mice, six groups were established to explore its immune-enhancing effects and mechanisms. Following two-dose immunization at 0 and 21 days, IgG antibody titers (ELISA), immune cell responses (flow cytometry), and safety/function of antigen-presenting cells (pathological sections, immunofluorescence staining) were detected. Results showed LIPO-SIM-Rh2 had a stable dispersion and a near-100 % encapsulation efficiency. Compared with other groups, it significantly increased anti-OVA specific IgG titer, promoted cellular immune response, up-regulated MHC-I molecule antigen presentation pathway, activated macrophages, promoted dendritic cell homing, and caused no obvious damage or inflammation to major organs. In conclusion, LIPO-SIM-Rh2 adjuvant has a feasible preparation method and strong immune-enhancing potential for vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.